XERIS BIOPHARMA HOLDINGS INC (XERS) Forecast, Price Target & Analyst Ratings
NASDAQ:XERS • US98422E1038
5.985 USD
+0.04 (+0.76%)
Last: Mar 4, 2026, 02:05 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for XERIS BIOPHARMA HOLDINGS INC (XERS).
Forecast Snapshot
Consensus Price Target
$11.37
+ 89.90% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$0.01
Revenue Estimate85.374M
ChartMill Buy Consensus
84.62%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.37
Upside
+ 89.90%
From current price of $5.99 to mean target of $11.37, Based on 13 analyst forecasts
Low
$8.08
Median
$10.20
High
$18.90
Price Target Revisions
1 Month
0.00%
3 Months
-3.11%
Price Target Summary
13 analysts have analysed XERS and the average price target is 11.37 USD. This implies a price increase of 89.9% is expected in the next year compared to the current price of 5.985.
The average price target has been revised downward by 3.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.62%
XERS was analyzed by 13 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about XERS.
In the previous month the buy percentage consensus was at a similar level.
XERS was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-10-29 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-07 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-11 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-28 | Oppenheimer | Initiate | Outperform |
| 2024-03-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-28 | Craig-Hallum | Initiate | Buy |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-27 | SVB Leerink | Maintains | Outperform |
| 2022-04-28 | Craig-Hallum | Initiate | Buy |
| 2022-02-16 | SVB Leerink | Maintains | Outperform |
| 2021-12-31 | SVB Leerink | Maintains | Outperform |
| 2021-12-31 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$0.01
Revenue Estimate85.374M
Revenue Q2Q42.01%
EPS Q2Q114.45%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
1.21%
EPS (1 Month)
0.00%
EPS (3 Months)
46.67%
Next Earnings Summary
XERS is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is 0.01 USD and the consensus revenue estimate is 85.37M USD.
The next earnings revenue estimate has been revised upward by 1.21% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 110.2M 122.18% | 163.914M 48.74% | 203.07M 23.89% | 293.98M 44.77% | 375.46M 27.72% | 444.27M 18.33% | 506.3M 13.96% | 622M 22.85% | 707.37M 13.73% | 533.05M -24.64% | 582.01M 9.18% | |
| EBITDA YoY % growth | -59.56M 43.07% | -31.68M 46.81% | -21.576M 31.89% | 56.049M 359.77% | 60.724M 8.34% | 109.99M 81.13% | 143.51M 30.48% | 184.86M 28.81% | 212.66M 15.04% | N/A | N/A | |
| EBIT YoY % growth | -71.8M 32.58% | -44.01M 38.70% | -33.646M 23.55% | 18.523M 155.05% | 55.243M 198.24% | 94.962M 71.90% | 134.35M 41.48% | 209.81M 56.17% | 285.86M 36.25% | N/A | N/A | |
| Operating Margin | -65.15% | -26.85% | -16.57% | 6.30% | 14.71% | 21.37% | 26.54% | 33.73% | 40.41% | N/A | N/A | |
| EPS YoY % growth | -0.70 53.95% | -0.45 35.71% | -0.38 15.56% | -0.04 97.37% | 0.19 1,951.30% | 0.36 96.14% | 0.57 57.30% | 0.94 64.29% | 1.13 20.65% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.01 114.45% | 0.04 530.95% | 0.06 | 0.08 33.03% | 0.02 135.29% | 0.02 -52.66% | 0.03 -50.41% | 0.04 -48.88% |
| Revenue Q2Q % growth | 85.374M 42.01% | 95.03M 32.84% | 101.93M 37.04% | 107.07M 24.78% | 97.41M 14.10% | 98.328M 3.47% | 99.756M -2.13% | 102.61M -4.17% |
| EBITDA Q2Q % growth | 14.076M 21,755.38% | 13.566M 28.67% | 15.198M -4.06% | 15.3M -25.56% | 19.482M 38.41% | 19.278M 42.11% | 21.42M 40.94% | 22.848M 49.33% |
| EBIT Q2Q % growth | 6.562M 312.36% | 12.648M 182.20% | 16.456M 144.48% | 19.448M 89.53% | 9.69M 47.67% | 9.486M -25.00% | 11.628M -29.34% | 13.056M -32.87% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
289.56%
EPS Next 5 Year
158.41%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
19.87%
Revenue Next 5 Year
19.20%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
68.61%
EBIT Next 5 Year
46.27%
XERIS BIOPHARMA HOLDINGS INC / XERS Forecast FAQ
What do analysts expect the price target to be for XERIS BIOPHARMA HOLDINGS INC (XERS)?
13 analysts have analysed XERS and the average price target is 11.37 USD. This implies a price increase of 89.9% is expected in the next year compared to the current price of 5.985.
Can you provide the upcoming earnings date for XERIS BIOPHARMA HOLDINGS INC?
XERIS BIOPHARMA HOLDINGS INC (XERS) will report earnings on 2026-05-06.
What are the consensus estimates for XERIS BIOPHARMA HOLDINGS INC (XERS) next earnings?
The consensus EPS estimate for the next earnings of XERIS BIOPHARMA HOLDINGS INC (XERS) is 0.01 USD and the consensus revenue estimate is 85.37M USD.
Can you provide the consensus rating for XERIS BIOPHARMA HOLDINGS INC stock?
The consensus rating for XERIS BIOPHARMA HOLDINGS INC (XERS) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.